CRESTBRIDGE
14.12.2020 15:32:17 CET | Business Wire | Press release
Crestbridge, the agile alternative for private equity and real estate administration solutions, has announced that it intends to acquire New Jersey based Ovation Fund Services. Ovation is a provider of fund administration, accounting and reporting services to US domestic private equity and real estate funds. The acquisition complements Crestbridge’s core service offering in both asset classes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005445/en/
Ovation will become part of the Crestbridge brand from 31 December 2020 and is the business’ seventh office. All Ovation employees will become members of the global Crestbridge team, ensuring continuity of client service and working with the wider Crestbridge Group to continue to grow and develop the current services offering.
The acquisition substantially expands Crestbridge’s presence in the US, where it already has an office in New York, and its ability to service private equity and real estate funds. It also enhances the multi-jurisdiction proposition to its client base as the new office complements Crestbridge’s existing network of offices in London, Luxembourg, Bahrain, the Cayman Islands, New York and Jersey (Channel Islands), providing access to its international team of experts for North American clients.
Commenting on the new office, Paul Perris, Chief Commercial Officer of the Crestbridge Group said: “This is another significant achievement in delivering our global expansion strategy and widening access to our solutions for private equity and real estate fund managers. In particular, this provides North American based clients access to European investment markets and turnkey solutions, which continues to be an increasingly strong trend, as well as supporting inward investment into North America. We are very much looking forward to supporting our global client base and helping facilitate their continued success.”
The New Jersey office will be headed by Scot Hadley, Ovation’s founder, who has over 23 years’ experience growing businesses and building long-term relationships within the private equity and real estate industry in the US and beyond. Scot established Ovation nearly four years ago, building a successful business with a loyal customer base. Prior to establishing Ovation, Scot spent 18 years of his career at Paladin Realty Partners, an institutional real estate fund manager, where he was one of ten founding members of the firm.
Scot commented: “We believe that bringing the quality and breadth of Crestbridge’s global capabilities together with our focus on the US markets is very attractive to current and prospective clients. Access to a global team with the same high standards as ours will be a huge benefit and we’re excited by the opportunities.”
The office is based in Morristown, New Jersey. The financial terms of the acquisition are not being disclosed.
This latest acquisition in North America also follows the announcement of ‘Crestbridge Fiduciary LLC’, created to better support families with US-based interests. This joint venture with Wyoming-based Willow Street was formed in response to exceptional client demand for Family Office Services and consolidates Crestbridge’s global expertise with Willow Street’s in-depth trust and fiduciary capability and high-calibre client base.
Ends.
Notes to editors
- We are a leading global administration, management & corporate governance solutions business.
- We provide a broad range of outsourced fiduciary, administrative, accounting and compliance services globally – our expertise spans services, asset classes and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers and ultra-high net worth families.
- Crestbridge employs over 350 people and has six international offices: Bahrain, Cayman Jersey, London, Luxembourg and New York.
- For our regulatory information please see here for more details.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
